GlassScriptPhysician profile
Arindam Bagchi
NPI 1922404367
$1,859.52
in general payments reported to CMS, 2019-2025
20 companies · $952 in 2025
The $952 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $16.14 · 2021: $36.79 · 2022: $101 · 2023: $263 · 2024: $328 · 2025: $952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,543.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $462.19 | 2022-2025 | Trodelvy |
| Pfizer INC. | $205.02 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $186.32 | 2020-2025 | Opdualag, Opdivo, Eliquis |
| Merck Sharp & Dohme LLC | $164.04 | 2022-2025 | Keytruda, Welireg, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $153.67 | 2021-2025 | |
| Daiichi Sankyo INC. | $139.88 | 2023-2025 | Enhertu, Datroway |
| Janssen Biotech, INC. | $129.28 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Tempus Ai, INC | $126.40 | 2025 | Xt Cdx |
| Karyopharm Therapeutics INC. | $47.48 | 2025 | Xpovio |
| Celgene Corporation | $40.41 | 2019 | |
| Array Biopharma INC | $36.40 | 2025 | Tukysa, Mektovi, Braftovi |
| Genentech USA, INC. | $32.46 | 2019-2023 | Phesgo, Perjeta |
| Lilly USA, LLC | $26.31 | 2024 | Verzenio, Jaypirca |
| Puma Biotechnology, INC. | $18.22 | 2024 | |
| Eisai INC. | $18.16 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $17.30 | 2025 | Padcev |
| Incyte Corporation | $17.23 | 2025 | Jakafi, Niktimvo |
| Janssen Pharmaceuticals, INC | $14.67 | 2021 | |
| Blueprint Medicines Corporation | $12.65 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arindam Bagchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.